Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
Christie M Ballantyne, Rene A Braeckman, Harold E Bays, John J Kastelein, James D Otvos, William G Stirtan, Ralph T Doyle Jr, Paresh N Soni, Rebecca A Juliano, Christie M Ballantyne, Rene A Braeckman, Harold E Bays, John J Kastelein, James D Otvos, William G Stirtan, Ralph T Doyle Jr, Paresh N Soni, Rebecca A Juliano
Abstract
Background: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved at a dose of 4 g/day as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG ≥ 500 mg/dL).
Objective: In this prespecified exploratory analysis from the ANCHOR study of patients at high cardiovascular risk with TG ≥ 200 and <500 mg/dL despite statin control of low-density lipoprotein cholesterol, we assessed the effects of IPE on lipoprotein particle concentration and size and examined correlations of atherogenic particles with apolipoprotein B (ApoB).
Methods: Nuclear magnetic resonance spectroscopy was used to measure lipoprotein particle concentration and size.
Results: Compared with placebo (n = 211), IPE 4 g/day (n = 216) significantly reduced concentrations of: total (12.2%, P = .0002), large (46.4%, P < .0001), and medium (12.1%, P = .0068) very-low-density lipoprotein (VLDL) particles; total (7.7%, P = .0017) and small (13.5%, P < .0001) LDL particles; and total (7.4%, P < .0001) and large (31.0%, P < .0001) high-density lipoprotein particles. Atherogenic lipoprotein particles (total VLDL and total LDL) correlated with ApoB at baseline (R(2) = 0.57) and week 12 (R(2) = 0.65) as did total LDL particle concentration at baseline (R(2) = 0.53) and week 12 (R(2) = 0.59). Compared with placebo, IPE 4 g/day significantly reduced VLDL (7.7%, P < .0001) and high-density lipoprotein (1.2%, P = .0014) particle sizes with a modest but significant increase in LDL particle size (0.5%, P = .0031).
Conclusions: Compared with placebo, treatment with IPE 4 g/day for 12 weeks reduced key atherogenic lipoprotein particle concentrations. At both baseline and end of study, atherogenic lipoprotein concentrations correlated with ApoB.
Keywords: Apolipoprotein B; Eicosapentaenoic acid; High-density lipoproteins; Hypertriglyceridemia; Icosapent ethyl; Low-density lipoproteins; Omega-3 fatty acid; Statin; Triglycerides.
Copyright © 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Source: PubMed